Bio-Path Holdings biopathholdings.com


Bio-Path Holdings is a biotechnology company developing targeted DNA therapeutics for blood cancers and solid tumors. The company's lead candidate is prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, for the treatment of acute myeloid leukemia (AML). Prexigebersen is being assessed in a Phase 2 trial in combination with front-line therapy. To date, prexigebersen has demonstrated an excellent safety profile and encouraging anti-leukemic activity in relapsed and refractory patients.

Bio-Path Holdings is a biotechnology company developing targeted DNA therapeutics for blood cancers and solid tumors. The company's lead candidate is prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, for the treatment of acute myeloid leukem...Show all

Company (IPO / Went public)

Phone: 832-742-1357

Fax:

4710 Bellaire Blvd
Suite 210
Bellaire, 77401
Texas, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Bio-Path Holdings $0M Mar 3, 2008

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Bio-Path Holdings Jobs

jobs by Indeed job
						search
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Combination therapy with liposomal antisense oligonucleotides Sep 15, 2017 Feb 23, 2021 Patent
P-ethoxy nucleic acids for liposomal formulation May 30, 2019 Jan 26, 2021 Patent
P-ethoxy nucleic acids for liposomal formulation Jul 21, 2017 Jul 02, 2019 Patent
P-ethoxy nucleic acids for liposomal formulation Oct 14, 2016 Aug 29, 2017 Patent
P-ethoxy nucleic acids for igf-1r inhibition Apr 19, 2018 Application
See all 6 patents